ICPT News and Press, Intercept Pharmaceuticals Inc. From 03/02/23

U.S. Ocaliva ® net sales of $77.2 million and $285.7 million for the fourth quarter and full year 2022, representing 13% and 10% growth over the prior year Worldwide Ocaliva ® non-GAAP adjusted net sales of $343.8 million for the full year 2022 As of December 3...

Intercept Pharma ( NASDAQ: ICPT ) is scheduled to announce Q4 earnings results on Thursday, March 2nd, before market open. The consensus EPS Estimate is -$0.46 (+62.6% Y/Y) and the consensus Revenue Estimate is $78.08M (-15.5% Y/Y). Over the last 1 year, ICPT has beaten EPS ...

MORRISTOWN, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chi...

Intercept Pharmaceuticals ( NASDAQ: ICPT ) and Apotex reached a settlement in regards to patent claims against Apotex over Intercept's rate liver disease treatment Ocaliva. Intercept ticked up 0.7%. The settlement was disclosed in a Delaware court filing on Friday. The settlem...

MORRISTOWN, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full-year...

The shares of Intercept Pharmaceuticals ( NASDAQ: ICPT ) added ~8% on Wednesday after the biotech announced an agreement with generic drugmaker Amneal Pharmaceuticals ( NYSE: AMRX ) to settle a patent dispute over the liver disease therapy Ocaliva. The Jan. 24 agreement ai...

Summary Due to what is seemingly a successful comeback, you can expect Intercept Pharmaceuticals to potentially deliver several-fold returns. Ocaliva's revenue for PBC alone is nearly enough to bank a net profit. The FDA recently accepted the New Drug Application of Ocaliva for non-...

Summary FDA has set June 22nd as the action date for its review of Ocaliva in NASH. Approval of Ocaliva in NASH is a long shot. Ocaliva’s growth in Primary Biliary Cholangitis is slowing. Intercept ( ICPT ) just announced that the FDA has set an action date ...

Intercept Pharmaceuticals ( NASDAQ: ICPT ) added ~2% pre-market Thursday after announcing that the FDA accepted its marketing application for obeticholic acid (OCA) as a treatment for pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH). The regulator has assign...

NDA is supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study demonstrating OCA’s improvement in liver fibrosis without worsening of NASH PDUFA target action date set for June 22, 2023 MORRISTOWN, N.J.,...